Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Komarno – page 9

274 clinical trials in Komarno, Slovakia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Komarno at a glance
274
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

274 trials in Komarno

Open in trial search

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Cardiac failure

Not yet recruiting

Efficacy and Safety of Fixed‑Dose Combination of Dapagliflozin, Bisoprolol Fumarate, and Eplerenone vs Usual Care in Hospitalized Acute Heart Failure Patients

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol Fumarate
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Type 2 diabetes mellitus+2

Not yet recruiting

A Study of Zenagamtide in Adults With Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Ponsegromab
  • Sponsor:Pfizer Inc.

Non-small cell lung cancer

Not yet recruiting

Study of Pembrolizumab, Vibostolimab, and Chemotherapy for Patients with Newly Diagnosed Resectable Stage II-IIIB Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm malignant

Not yet recruiting

Study on the Effectiveness and Safety of Luveltamab Tazevibulin Compared to Chemotherapy in Women with Relapsed Platinum-resistant Ovarian Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Sutro Biopharma Inc.

Fallopian tube cancer+1

Not yet recruiting

Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Slovakia

The busiest research cities in the country

All 88 cities in Slovakia

Clinical research in Komarno

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on non-small cell lung cancer and advanced breast cancer treatments, evaluating new therapeutic combinations and targeted approaches.

  • Breast Cancer Studies
  • Lung Cancer Therapies
  • Targeted Treatment Combinations

Multiple studies investigating hormone receptor-positive and HER2-negative breast cancer treatments with novel drug combinations.

02 Cardiovascular Medicine

Research centered on preventing and treating cardiovascular diseases, including studies on stroke prevention and innovative treatments for major cardiovascular events.

  • Stroke Prevention
  • Lipoprotein Management
  • Cardiovascular Risk Reduction

Trials evaluating new compounds for reducing cardiovascular events and improving patient outcomes.

03 Women's Health

Studies examining new approaches in contraceptive medicine and reproductive health, including novel delivery systems and long-term efficacy evaluations.

  • Contraceptive Solutions
  • Reproductive Health
  • Long-term Safety Studies

Clinical research focusing on innovative contraceptive methods and their safety profiles.

04 Dermatology

Research investigating treatments for chronic spontaneous urticaria, examining long-term efficacy and safety of new therapeutic options.

  • Urticaria Management
  • Long-term Treatment Effects
  • Patient Tolerance Studies

Evaluating advanced treatments for chronic skin conditions with focus on sustained symptom control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.